The groundbreaking success of Viagra undeniably reshaped the pharmaceutical landscape, but betting in companies primarily reliant on unbranded versions presents a uncertain picture. Despite early returns were substantial, the cessation of patents and the rise of less expensive alternatives have eroded the customer base. Consequently, a thorough eva